Importantly, in acting as a receptor antagonist for TLR2/1, MALP-2 may attenuate TLR2/1-mediated platelet activation during sepsis and other clinical conditions that are a potent source of TLR-triggering ligands. This evidence concerns the gene TLR2 and Sepsis.